Skip to content

Study · Animal study (in vivo) · rat · 1999

14 results

[The effect of bromantane on the erythro- and leukocytic profile of the peripheral blood in rats].

Bugaeva LI, Spasov AA, Morozov IS

Eksperimental'naia i klinicheskaia farmakologiia1 Jul 1999

PMID10513335 (opens in a new tab)PepBankPUB-10513335
Publisher pageAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, chronic bromantan injection raised hemoglobin levels.

    In plain wordsIn rats, chronic bromantan injection raised hemoglobin levels.

    Peptide
    Bromantane
    Outcome
    IncreaseHemoglobin
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In chronic injection in a dose of 30 mg/kg bromantan raised the level of hemoglobin and leukocytes.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, chronic bromantan injection raised leukocyte levels.

    In plain wordsIn rats, chronic bromantan injection raised white blood cell levels.

    Peptide
    Bromantane
    Outcome
    IncreaseLeukocytes
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    30 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In chronic injection in a dose of 30 mg/kg bromantan raised the level of hemoglobin and leukocytes.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 150 mg/kg initially increased erythrocytes during three months and subsequently reduced them.

    In plain wordsIn rats, bromantan first raised red blood cell levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedErythrocytes
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    150 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 600 mg/kg initially increased erythrocytes during three months and subsequently reduced them.

    In plain wordsIn rats, bromantan first raised red blood cell levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedErythrocytes
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    600 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 150 mg/kg initially increased hemoglobin during three months and subsequently reduced it.

    In plain wordsIn rats, bromantan first raised hemoglobin levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedHemoglobin
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    150 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 600 mg/kg initially increased hemoglobin during three months and subsequently reduced it.

    In plain wordsIn rats, bromantan first raised hemoglobin levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedHemoglobin
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    600 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 150 mg/kg initially increased leukocytes during three months and subsequently reduced them.

    In plain wordsIn rats, bromantan first raised white blood cell levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedLeukocytes
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    150 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantan at 600 mg/kg initially increased leukocytes during three months and subsequently reduced them.

    In plain wordsIn rats, bromantan first raised white blood cell levels and then lowered them.

    Peptide
    Bromantane
    Outcome
    MixedLeukocytes
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    600 mg/kg · injectionAs given in this study (rat).

    Source sentences

    Summary
    In doses of 150 and 600 mg/kg it increased at first (3 months) and then reduced the level of erythrocytes, hemoglobin, and leukocytes.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In rats, reversible poikilocytosis occurred with bromantan treatment.

    In plain wordsIn rats, reversible abnormal red blood cell shapes occurred with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicablePoikilocytosis
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Reversible poikilocytosis, granulocytosis, and agranulocytosis were encountered.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In rats, reversible granulocytosis occurred with bromantan treatment.

    In plain wordsIn rats, reversible excess granulocytes occurred with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableGranulocytosis
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Reversible poikilocytosis, granulocytosis, and agranulocytosis were encountered.
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In rats, reversible agranulocytosis occurred with bromantan treatment.

    In plain wordsIn rats, reversible loss of granulocytes occurred with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableAgranulocytosis
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Reversible poikilocytosis, granulocytosis, and agranulocytosis were encountered.
  12. 12AnimalAnimal study (in vivo)Safety outcome

    In rats, hepatocyte hyperchromatosis appeared with bromantan treatment.

    In plain wordsIn rats, liver cells showed increased staining with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableHepatocyte hyperchromatosis
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Hyperchromatosis and hypertrophy of the hepatocytes were found in the tissues of the liver and hemosiderosis was discovered in the spleen.
  13. 13AnimalAnimal study (in vivo)Safety outcome

    In rats, hepatocyte hypertrophy appeared with bromantan treatment.

    In plain wordsIn rats, enlarged liver cells appeared with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableHepatocyte hypertrophy
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Hyperchromatosis and hypertrophy of the hepatocytes were found in the tissues of the liver and hemosiderosis was discovered in the spleen.
  14. 14AnimalAnimal study (in vivo)Safety outcome

    In rats, splenic hemosiderosis appeared with bromantan treatment.

    In plain wordsIn rats, iron pigment accumulated in the spleen with bromantan treatment.

    Peptide
    Bromantane
    Outcome
    Not applicableSplenic hemosiderosis
    Study

    ratn: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · injectionAs given in this study (rat).

    Source sentences

    Summary
    Hyperchromatosis and hypertrophy of the hepatocytes were found in the tissues of the liver and hemosiderosis was discovered in the spleen.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.